Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Details)

v3.5.0.2
Segment Reporting (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Segment Reporting Information [Line Items]    
Net revenues $ 948 $ 1,851
Research and development expenses 3,156 3,495
General and administrative expenses 7,685 5,022
Operating loss (9,893) (6,666)
Interest expense (807) 0
Interest and other income 43 41
Consolidated net loss (10,657) (6,625)
Total assets 51,600 12,494
Fixed assets, net 25,574 13
Intangible assets, net 2,092 2,360
Depreciation expense 577 5
Amortization of intangible assets 363 358
iBio Brazil [Member]    
Segment Reporting Information [Line Items]    
Net revenues 0 0
Research and development expenses 0 0
General and administrative expenses 22 93
Operating loss (22) (93)
Interest expense 0 0
Interest and other income 0 0
Consolidated net loss (22) (93)
Total assets 20 46
Fixed assets, net 0 10
Intangible assets, net 0 0
Depreciation expense 2 2
Amortization of intangible assets 0 0
iBio United States [Member]    
Segment Reporting Information [Line Items]    
Net revenues 948 1,851
Research and development expenses 3,156 3,495
General and administrative expenses 7,663 4,929
Operating loss (9,871) (6,573)
Interest expense (807) 0
Interest and other income 43 41
Consolidated net loss (10,635) (6,532)
Total assets 51,580 12,448
Fixed assets, net 25,574 3
Intangible assets, net 2,092 2,360
Depreciation expense 575 3
Amortization of intangible assets $ 363 $ 358